Advance care planning in older patients with acute myeloid leukemia and myelodysplastic syndromes.

Acute myeloid leukemia Advance care planning Hematologic malignancy Myelodysplastic syndromes Qualitative study

Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 27 07 2022
revised: 29 08 2022
accepted: 02 09 2022
pubmed: 14 9 2022
medline: 3 3 2023
entrez: 13 9 2022
Statut: ppublish

Résumé

Older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have worse survival rates compared to younger patients, and experience more intense inpatient healthcare at the end of life (EOL) compared to patients with solid tumors. Advance care planning (ACP) has been shown to limit aggressive and burdensome care at EOL for patients with AML and MDS. The purpose of this study was to better understand ACP from the perspective of clinicians, older patients with AML and MDS, and their caregivers. We conducted semi-structured interviews with 45 study participants. Interviews were audio-recorded and transcribed. Open coding and focused content analysis were used to organize data and develop and contextualize categories and subcategories. Guided by our specific aims, we developed four themes: (1) The language of ACP and medical order for life-sustaining treatment (MOLST) does not resonate with patients, (2) There is no uniform consensus on when ACP is currently happening, (3) Oncology clinician-perceived barriers to ACP (e.g., patient discomfort, patient lack of knowledge, and lack of time), and (4) Patients felt that they are balancing fear and hope when navigating their AML or MDS diagnosis. The results of this study can be used to develop interventions to promote serious illness conversations for patients with AML and MDS and their caregivers to ensure that patient care aligns with patient values.

Identifiants

pubmed: 36100548
pii: S1879-4068(22)00222-3
doi: 10.1016/j.jgo.2022.09.003
pmc: PMC9974785
mid: NIHMS1860479
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101374

Subventions

Organisme : NCI NIH HHS
ID : R00 CA237744
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG059206
Pays : United States
Organisme : NIA NIH HHS
ID : K02 AG062745
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG055693
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA237744
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG059206
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Loh has served as a consultant to Pfizer and Seattle Genetics and has received honoraria from Pfizer.

Références

Oncologist. 2021 Apr;26(4):e686-e693
pubmed: 33321004
Blood Rev. 2019 Jul;36:70-87
pubmed: 31101526
JAMA. 2022 Jan 25;327(4):321-322
pubmed: 34994773
Am J Manag Care. 2014 Mar;20(5 Spec No.):E1
pubmed: 25618629
Cancer. 2009 Jul 1;115(13):2903-11
pubmed: 19452536
Cancer. 2016 Apr 15;122(8):1209-15
pubmed: 26914833
J Oncol Pract. 2017 Oct;13(10):e881-e888
pubmed: 28727486
Blood. 2018 Aug 16;132(7):717-726
pubmed: 29848484
JAMA. 2011 Sep 14;306(10):1122-9
pubmed: 21828309
Issues Ment Health Nurs. 2019 Mar;40(3):233-239
pubmed: 30508400
J Oncol Pract. 2013 Jul;9(4):e129-35
pubmed: 23942929
Fam Med Community Health. 2019 Apr 1;7(2):e000040
pubmed: 32148701
JAMA. 2021 Oct 26;326(16):1575-1576
pubmed: 34623373
Cancer. 2020 Feb 1;126(3):515-522
pubmed: 31593321
J Clin Oncol. 2016 Sep 10;34(26):3126-32
pubmed: 27400944
Arch Intern Med. 2012 Aug 13;172(15):1133-42
pubmed: 22777380
Blood. 2020 Dec 3;136(23):2715-2719
pubmed: 32698198
J Clin Oncol. 2017 Mar 10;35(8):834-841
pubmed: 28029308
J Clin Oncol. 2017 Oct 20;35(30):3417-3424
pubmed: 28783450
JCO Oncol Pract. 2020 Sep;16(9):e875-e883
pubmed: 32282265
Leuk Lymphoma. 2021 Feb;62(2):387-398
pubmed: 33040623
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Am J Hosp Palliat Care. 2019 Jul;36(7):564-570
pubmed: 30700127
Blood Adv. 2022 Nov 8;6(21):5707-5710
pubmed: 35930701
Blood Adv. 2021 Dec 28;5(24):5554-5564
pubmed: 34525170
BMC Fam Pract. 2020 May 25;21(1):94
pubmed: 32450812
Semin Oncol Nurs. 2018 Aug;34(3):316-326
pubmed: 30100366
Am J Hematol. 2019 Jun;94(6):E169-E172
pubmed: 30883871
Ann Palliat Med. 2020 Feb;9(Suppl 1):S75-S79
pubmed: 31865746
J Pain Symptom Manage. 2018 Apr;55(4):1068-1076
pubmed: 29289656
Blood. 2013 May 23;121(21):4287-94
pubmed: 23550038
Tumori. 2009 May-Jun;95(3):303-10
pubmed: 19688968
Cancer. 2014 May 15;120(10):1572-8
pubmed: 24549743
Psychooncology. 2017 Dec;26(12):2063-2068
pubmed: 27862591
Blood Rev. 2019 Mar;34:1-15
pubmed: 30314642
Am J Hosp Palliat Care. 2020 Sep;37(9):692-700
pubmed: 31867978
Cancer. 2015 Aug 15;121(16):2840-8
pubmed: 25926135
Oncologist. 2015 Nov;20(11):1304-11
pubmed: 26446232
J Pain Symptom Manage. 2014 Nov;48(5):839-51
pubmed: 24703943
J Clin Oncol. 2008 Sep 1;26(25):4131-7
pubmed: 18757326
J Clin Oncol. 2016 Mar 20;34(9):972-9
pubmed: 26811524
J Am Geriatr Soc. 2016 Oct;64(10):1988-1995
pubmed: 27627675
Cancer. 2022 Mar 15;128(6):1339-1345
pubmed: 34787930
J Natl Compr Canc Netw. 2016 Jul;14(7):859-66
pubmed: 27407126
Sci Rep. 2020 Dec 3;10(1):21145
pubmed: 33273653
J Palliat Med. 2018 Feb;21(2):225-228
pubmed: 28795860
Ann Am Thorac Soc. 2021 Sep;18(9):1533-1539
pubmed: 33400904

Auteurs

Marissa LoCastro (M)

School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA. Electronic address: Marissa_locastro@urmc.rochester.edu.

Chandrika Sanapala (C)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Chandrika.sanapala@burrell.edu.

Jason H Mendler (JH)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Jason_mendler@urmc.rochester.edu.

Sally Norton (S)

School of Nursing, University of Rochester, Rochester, NY, USA. Electronic address: Sally_norton@urmc.rochester.edu.

Rachelle Bernacki (R)

Department of Palliative Care, Harvard Medical School, Boston, MA, USA. Electronic address: RachelleE_Bernacki@DFCI.HARVARD.EDU.

Thomas Carroll (T)

Division of General Medicine and Palliative Care, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Thomas_carroll@urmc.rochester.edu.

Heidi Klepin (H)

Department of Hematology/Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: hklepin@wakehealth.edu.

Erin Watson (E)

Princeton University, NJ, USA. Electronic address: eewatson@princeton.edu.

Jane Liesveld (J)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Jane_liesveld@urmc.rochester.edu.

Eric Huselton (E)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Eric_huselton@urmc.rochester.edu.

Kristen O'Dwyer (K)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Kristen_odwyer@urmc.rochester.edu.

Andrea Baran (A)

Department of Biostatistics and Computational Biology, University of Rochester, New York, USA. Electronic address: Andrea_baran@urmc.rochester.edu.

Marie Flannery (M)

School of Nursing, University of Rochester, Rochester, NY, USA. Electronic address: Marie_flannery@urmc.rochester.edu.

Benzi M Kluger (BM)

Division of General Medicine and Palliative Care, Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA; Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Benzi_kluger@urmc.rochester.edu.

Kah Poh Loh (KP)

Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Kahpoh_loh@urmc.rochester.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH